Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2018 Sep 6;14(2):188–199. doi: 10.1007/s11481-018-9804-7

Table 4.

Summary of Appendix Tables 10–17, which address two proteins at a time for the early epoch (4a) and separately for the late epoch (4b).a

4a. early epoch
TNF-α IL-8 ICAM-1
Proteins W I S E W I S E W I S E
IL-6R V V V V V V
MMP-9 V Λ V Λ V
RANTES V V V V V V
EPO Λ Λ Λ Λ
NT-4 V V V V
BDNF V V V V V V
bFGF Λ V V V V
IGF-1 V V V V V
VEGF V V V V V V V V
VEGF-R1 V V V V V V V V
VEGF-R2 V V V V V
PIGF V V V V V V V
Ang-1 V V V V V V V V
Ang-2
4b. late epoch
TNF-α IL-8 ICAM-1
Proteins W I S E W I S E W I S E
IL-6R V V
MMP-9 V V
RANTES V V V V
EPO V V V V V V
NT-4 V V V V
BDNF V V
bFGF V V
IGF-1 V V V V
VEGF V V
VEGF-R1 V V V Λ V
VEGF-R2 Λ V
PIGF V V V V
Ang-1 V
Ang-2 V V V V
a

The inflammation-related protein is identified at the top of each set of columns, and the neurotrophic proteins are identified on the left. Λ indicates increased risk of a Z-score < −1 on the executive dysfunction assessment(s) identified just below the inflammation-related protein, while V indicates decreased risk. W indicates a DAS-II Working Memory Z-score ≤ −1, I indicates a NEPSY-II Inhibition-inhibition Z- score ≤ −1, S indicates a NEPSY-II Inhibition-Switching Z- score ≤ −1, and E indicates the executive dysfunction composite defined as a Z-score ≤ −1 on all three assessments.